CYP2C9 (Cytochrome P450 2C9) variants and mutations
CYP2C9 (also known as Cytochrome P450 2C9) is a human protein-coding gene encoding a cytochrome P450 2C9 protein. An endoplasmic-reticulum cytochrome P450 enzyme that oxidizes drugs and endogenous molecules such as fatty acids and steroids. Its activity varies between individuals, so CYP2C9 variation is important in pharmacogenetics and medication-response research. This analysis covers 1,033 CYP2C9 variants and mutations. Of these, 97% have computational variant effect predictions. Disease context includes response to anticoagulant, Abnormality of the skeletal system, and Hypoglycemia. Example CYP2C9 variants include M1?, D2N, and D2V.
Variant analysis overview
- Gene: CYP2C9
- Protein: Cytochrome P450 2C9
- UniProt accession: P11712
- Organism: Homo sapiens
- Variants analyzed: 1033
- Variant scope: all variants
- Completed: 2026-07-21
Variant and mutation evidence
- Variant composition: 758 unspecified-consequence records; 116 synonymous variants; 121 missense variants; 8 stop-gained variants; 22 frameshift variants; 1 in-frame insertions; 4 in-frame deletions; 2 splice-region variants; 1 substitution
- Prediction scores: 1,002 variants have prediction scores (97% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: response to anticoagulant, Abnormality of the skeletal system, Hypoglycemia, head and neck squamous cell carcinoma, hepatocellular carcinoma, colorectal carcinoma, placenta praevia, COVID-19, pulmonary hypertension, primary, 1, Blindness, atrial fibrillation, hypertensive disorder.
Protein structure and variant hotspots
- Protein features: 1 binding sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, PharmGKB, MaveDB, LitVar.
Notable CYP2C9 variants
Examples include M1?, D2N, D2V, D2D, S3C, S3F, S3P, S3Y. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, rs150891702, NCI-TCGA Cosmic COSV5324, MetaLR 0.47, MetaSVM -0.46, Variant assessed as somatic; high impact.
- D2N (p.Asp2Asn), cosmic curated COSV53254, TOPMed rs139414138, gnomAD rs139414138, REVEL 0.18, CADD 21.60
- D2V (p.Asp2Val), gnomAD rs1298240347, REVEL 0.17, CADD 14.80
- D2D (p.Asp2Asp), gnomAD 10-94938688-T-C, CADD 0.87
- S3C (p.Ser3Cys), ExAC rs774250598, TOPMed rs774250598, gnomAD rs774250598, REVEL 0.05, CADD 0.32
- S3F (p.Ser3Phe), cosmic curated COSV10729, ExAC rs774250598, TOPMed rs774250598, gnomAD rs774250598, REVEL 0.10, CADD 0.51
- S3P (p.Ser3Pro), rs1213307859, gnomAD rs1213307859, REVEL 0.09, CADD 0.08, Variant assessed as somatic; moderate impact.
- S3Y (p.Ser3Tyr), cosmic curated COSV53247, ExAC rs774250598, TOPMed rs774250598, gnomAD rs774250598, REVEL 0.09, CADD 2.16
- L4F (p.Leu4Phe), cosmic curated COSV53250, ExAC rs767472668, TOPMed rs767472668, gnomAD rs767472668, REVEL 0.05, CADD 0.00
- L4L (p.Leu4Leu), rs2031305356, gnomAD 10-94938694-T-C, CADD 0.32
- V5A (p.Val5Ala), 1000Genomes rs138957855, ESP rs138957855, ExAC rs138957855, TOPMed rs138957855, REVEL 0.18, CADD 8.82
- V5L (p.Val5Leu), gnomAD rs978647639, REVEL 0.04, CADD 3.65
- V5M (p.Val5Met), gnomAD 10-94938695-G-A, REVEL 0.11, MetaLR 0.15
- V5V (p.Val5Val), gnomAD 10-94938697-G-C, CADD 0.71
- V6F (p.Val6Phe), TOPMed rs1312272026, gnomAD rs1312272026, REVEL 0.05, CADD 0.21, Uncertain significance, not specified
- V6V (p.Val6Val), gnomAD 10-94938700-C-G, CADD 1.41
- L7F (p.Leu7Phe), ExAC rs763598557, TOPMed rs763598557, gnomAD rs763598557, REVEL 0.11, CADD 10.70
- L7H (p.Leu7His), ExAC rs753290446, TOPMed rs753290446, REVEL 0.35, CADD 22.30
- V8V (p.Val8Val), gnomAD 10-94938706-G-T, CADD 0.77
- L9F (p.Leu9Phe), NCI-TCGA TCGA novel, Ensembl rs2031306151, REVEL 0.03, CADD 5.42, Uncertain significance, not specified
- L9P (p.Leu9Pro), gnomAD 10-94938708-T-C, REVEL 0.47, MetaLR 0.59
- L9L (p.Leu9Leu), rs758860991, gnomAD 10-94938709-C-T, CADD 0.57
- C10R (p.Cys10Arg), gnomAD 10-94938710-T-C, REVEL 0.16, MetaLR 0.15
- C10Y (p.Cys10Tyr), gnomAD 10-94938711-G-A, REVEL 0.10, MetaLR 0.18
- L11F (p.Leu11Phe), NCI-TCGA Cosmic COSV5325, cosmic curated COSV53252, MetaLR 0.20, MetaSVM -0.85, Variant assessed as somatic; moderate impact.
- L11P (p.Leu11Pro), TOPMed rs2031306271, REVEL 0.49, CADD 22.50
- L11I (p.Leu11Ile), gnomAD 10-94938713-C-A, REVEL 0.06, MetaLR 0.21
- L11L (p.Leu11Leu), rs753939005, gnomAD 10-94938715-C-T, CADD 1.88
- S12* (p.Ser12Ter), Ensembl rs2031306386, CADD 32.00
- S12L (p.Ser12Leu), NCI-TCGA Cosmic COSV5324, cosmic curated COSV53246, REVEL 0.08, CADD 10.80, Variant assessed as somatic; moderate impact.
- S12P (p.Ser12Pro), gnomAD 10-94938716-T-C, REVEL 0.31, MetaLR 0.27
- S12S (p.Ser12Ser), gnomAD 10-94938718-A-G, CADD 1.24
- C13R (p.Cys13Arg), Ensembl rs2031306438, MetaLR 0.20, MetaSVM -0.82
- C13Y (p.Cys13Tyr), ExAC rs752108458, gnomAD rs752108458, REVEL 0.08, CADD 8.39
- L14L (p.Leu14Leu), gnomAD 10-94938724-G-A, CADD 1.22
- L14F (p.Leu14Phe), gnomAD 10-94938724-G-T, REVEL 0.20, MetaLR 0.23
- L15I (p.Leu15Ile), rs2031306544, ClinGen CA377675470, cosmic curated COSV53246, ClinVar RCV004133235, REVEL 0.06, CADD 2.35, Uncertain significance, not specified
- L15F (p.Leu15Phe), gnomAD 10-94938725-C-T, REVEL 0.06, MetaLR 0.20
- L16L (p.Leu16Leu), rs955864728, gnomAD 10-94938730-C-G, CADD 0.66
- L17F (p.Leu17Phe), gnomAD rs1401973837, REVEL 0.08, CADD 0.08
- L17L (p.Leu17Leu), rs755305395, gnomAD 10-94938733-T-G, CADD 0.28
- S18L (p.Ser18Leu), cosmic curated COSV53247, Ensembl rs1564706179, REVEL 0.19, CADD 12.30
- S18S (p.Ser18Ser), rs544425883, gnomAD 10-94938736-A-G, CADD 0.27
- L19I (p.Leu19Ile), rs67807361, cosmic curated COSV53246, UniProt VAR 018862, 1000Genomes rs67807361, REVEL 0.06, CADD 1.08, Benign, in allele CYP2C9*7
- L19R (p.Leu19Arg), gnomAD rs1397713285, REVEL 0.15, CADD 15.40
- L19L (p.Leu19Leu), gnomAD 10-94938739-C-G, CADD 1.29
- W20C (p.Trp20Cys), 1000Genomes rs533309841, ExAC rs533309841, TOPMed rs533309841, gnomAD rs533309841, REVEL 0.35, CADD 23.40
- W20* (p.Trp20Ter), gnomAD 10-94938742-G-A, CADD 34.00
- R21K (p.Arg21Lys), gnomAD 10-94938744-G-A, REVEL 0.05, CADD 0.23
- Q22* (p.Gln22Ter), ExAC rs777845146, TOPMed rs777845146, gnomAD rs777845146, CADD 33.00
- Q22R (p.Gln22Arg), gnomAD 10-94938747-A-G, REVEL 0.11, CADD 11.90
- S23G (p.Ser23Gly), Ensembl rs1589403412
- S23N (p.Ser23Asn), ExAC rs749413247, TOPMed rs749413247, gnomAD rs749413247, MetaLR 0.12, MetaSVM -1.07
- S23T (p.Ser23Thr), ExAC rs749413247, TOPMed rs749413247, gnomAD rs749413247, REVEL 0.07, CADD 0.41
- S23R (p.Ser23Arg), gnomAD 10-94938751-C-G, REVEL 0.08, CADD 0.00
- S23S (p.Ser23Ser), rs1279111343, gnomAD 10-94938751-C-T, CADD 0.07
- S24P (p.Ser24Pro), TOPMed rs1440551734, gnomAD rs1440551734, REVEL 0.08, CADD 6.46
- G25G (p.Gly25Gly), rs2031307508, gnomAD 10-94938757-G-A, CADD 1.23
- R26I (p.Arg26Ile), ExAC rs770945879, gnomAD rs770945879, REVEL 0.15, CADD 10.40
- R26K (p.Arg26Lys), ExAC rs770945879, gnomAD rs770945879, REVEL 0.07, CADD 0.14
- R26S (p.Arg26Ser), NCI-TCGA Cosmic COSV9958, cosmic curated COSV99582, Variant assessed as somatic; moderate impact.
- R26E (p.Arg26Glu), rs1320227926, gnomAD 10-94938754-TG-T, CADD 11.40
- R26G (p.Arg26Gly), gnomAD 10-94938758-A-G, REVEL 0.15, CADD 15.40
- R26R (p.Arg26Arg), gnomAD 10-94938760-A-G, CADD 4.49
- G27E (p.Gly27Glu), NCI-TCGA Cosmic COSV5324, cosmic curated COSV53246, REVEL 0.09, CADD 7.57, Variant assessed as somatic; moderate impact.
- G27* (p.Gly27Ter), gnomAD 10-94938761-G-T, CADD 24.90
- G27R (p.Gly27Arg), gnomAD 10-94938761-G-A, REVEL 0.02, CADD 0.93
- K28N (p.Lys28Asn), rs762769573, gnomAD 10-94938762-GA-G, CADD 1.32
- K28E (p.Lys28Glu), gnomAD 10-94938764-A-G, REVEL 0.07, CADD 14.40
- L29R (p.Leu29Arg), gnomAD rs1225059208, REVEL 0.16, CADD 22.40
- L29I (p.Leu29Ile), gnomAD 10-94938767-C-A, REVEL 0.11, CADD 16.30
- L29V (p.Leu29Val), gnomAD 10-94938767-C-G, REVEL 0.12, CADD 10.90
- L29F (p.Leu29Phe), gnomAD 10-94938767-C-T, REVEL 0.07, CADD 12.10
- L29L (p.Leu29Leu), gnomAD 10-94938769-C-A, CADD 0.58
- P30L (p.Pro30Leu), ESP rs142240658, ExAC rs142240658, TOPMed rs142240658, gnomAD rs142240658, REVEL 0.56, CADD 22.60, Variant assessed as somatic; high impact.
- P30S (p.Pro30Ser), NCI-TCGA Cosmic COSV5324, cosmic curated COSV53249, REVEL 0.52, CADD 22.50, Variant assessed as somatic; moderate impact.
- P31S (p.Pro31Ser), Ensembl rs532873887, REVEL 0.24, CADD 22.70
- P31T (p.Pro31Thr), Ensembl rs532873887, MetaLR 0.34, MetaSVM -0.08
- P31L (p.Pro31Leu), gnomAD 10-94938774-C-T, REVEL 0.32, CADD 23.80
- G32D (p.Gly32Asp), gnomAD rs1485077340, REVEL 0.44, CADD 24.00
- G32R (p.Gly32Arg), ExAC rs771975804, gnomAD rs771975804, REVEL 0.42, CADD 24.30
- G32S (p.Gly32Ser), gnomAD 10-94938776-G-A, REVEL 0.44, CADD 24.40
- G32A (p.Gly32Ala), gnomAD 10-94938777-G-C, REVEL 0.41, CADD 23.70
- G32G (p.Gly32Gly), rs28371673, gnomAD 10-94938778-C-G, CADD 2.13
- P33L (p.Pro33Leu), gnomAD rs949431436, REVEL 0.39, CADD 23.70
- P33S (p.Pro33Ser), gnomAD 10-94938779-C-T, REVEL 0.34, CADD 23.20
- P33P (p.Pro33Pro), rs1425392164, gnomAD 10-94938781-C-T, CADD 4.48
- T34A (p.Thr34Ala), ExAC rs760304881, TOPMed rs760304881, gnomAD rs760304881, REVEL 0.04, CADD 9.05
- T34S (p.Thr34Ser), ExAC rs760304881, TOPMed rs760304881, gnomAD rs760304881, REVEL 0.06, CADD 13.20
- T34T (p.Thr34Thr), rs763682133, gnomAD 10-94938784-T-C, CADD 5.50
- P35L (p.Pro35Leu), rs753338224, NCI-TCGA Cosmic COSV9958, cosmic curated COSV99582, ExAC rs753338224, REVEL 0.23, CADD 23.10, Variant assessed as somatic; moderate impact.
- P35S (p.Pro35Ser), rs2493000572, ClinGen CA377675598, ClinVar RCV004344352, REVEL 0.15, CADD 22.10, Uncertain significance, not specified
- P35T (p.Pro35Thr), gnomAD 10-94938785-C-A, REVEL 0.17, CADD 21.70
- P35P (p.Pro35Pro), rs1189469498, gnomAD 10-94938787-T-C, CADD 6.79
- L36R (p.Leu36Arg), ExAC rs761289446, gnomAD rs761289446, REVEL 0.57, CADD 23.40
- L36L (p.Leu36Leu), rs1311013151, gnomAD 10-94938790-C-T, CADD 0.62
- P37A (p.Pro37Ala), ExAC rs764766385, gnomAD rs764766385, REVEL 0.28, CADD 22.30
- P37L (p.Pro37Leu), NCI-TCGA TCGA novel, gnomAD rs2031308640, REVEL 0.26, CADD 23.20, Variant assessed as somatic; moderate impact.
- P37S (p.Pro37Ser), rs764766385, NCI-TCGA Cosmic COSV5324, cosmic curated COSV53246, ExAC rs764766385, REVEL 0.28, CADD 22.80, Variant assessed as somatic; moderate impact.
- P37P (p.Pro37Pro), rs2031308685, gnomAD 10-94938793-A-G, CADD 0.15
- V38A (p.Val38Ala), NCI-TCGA Cosmic COSV5325, cosmic curated COSV53252, MetaLR 0.27, MetaSVM -0.66, Variant assessed as somatic; moderate impact.
- V38E (p.Val38Glu), gnomAD rs1414284836, REVEL 0.43, CADD 22.80
- V38M (p.Val38Met), NCI-TCGA Cosmic COSV5324, REVEL 0.12, CADD 9.88, Variant assessed as somatic; moderate impact.
- V38L (p.Val38Leu), gnomAD 10-94938794-G-C, REVEL 0.10, CADD 0.19
- V38V (p.Val38Val), rs2031308785, gnomAD 10-94938796-G-T, CADD 0.03
- I39F (p.Ile39Phe), ExAC rs752057153, gnomAD rs752057153, REVEL 0.17, CADD 3.79
- I39T (p.Ile39Thr), gnomAD 10-94938798-T-C, REVEL 0.43, CADD 22.80
- I39M (p.Ile39Met), gnomAD 10-94938799-T-G, REVEL 0.23, CADD 17.40
- G40R (p.Gly40Arg), cosmic curated COSV10459, TOPMed rs1364419386, gnomAD rs1364419386, REVEL 0.42, CADD 24.70
- G40V (p.Gly40Val), ExAC rs755537965, TOPMed rs755537965, gnomAD rs755537965, REVEL 0.45, CADD 24.20
- G40G (p.Gly40Gly), gnomAD 10-94938802-A-G, CADD 6.83
- N41D (p.Asn41Asp), TOPMed rs2031308986, REVEL 0.30, CADD 23.50
- N41I (p.Asn41Ile), ExAC rs767866067, TOPMed rs767866067, gnomAD rs767866067, REVEL 0.35, CADD 23.70
- N41K (p.Asn41Lys), gnomAD 10-94938804-AT-A, CADD 4.87
- I42N (p.Ile42Asn), TOPMed rs1046460985, REVEL 0.30, CADD 22.10, Uncertain significance, not specified
- I42V (p.Ile42Val), ExAC rs111639787, TOPMed rs111639787, gnomAD rs111639787, REVEL 0.07, CADD 1.06
- I42T (p.Ile42Thr), gnomAD 10-94938807-T-C, REVEL 0.18, CADD 13.00
- I42I (p.Ile42Ile), gnomAD 10-94938808-C-A, CADD 0.44
- L43P (p.Leu43Pro), Ensembl rs1589403479, REVEL 0.38, CADD 19.60
- L43L (p.Leu43Leu), rs1205193890, gnomAD 10-94938809-C-T, CADD 2.01
- Q44H (p.Gln44His), TOPMed rs1042669734, gnomAD rs1042669734, NCI-TCGA TCGA novel, REVEL 0.22, CADD 20.30, Variant assessed as somatic; moderate impact.
- Q44K (p.Gln44Lys), Ensembl rs2134340242, MetaLR 0.28, MetaSVM -0.73
- Q44Q (p.Gln44Gln), gnomAD 10-94938814-G-A, CADD 1.65
- I45M (p.Ile45Met), ExAC rs756322378, TOPMed rs756322378, gnomAD rs756322378, REVEL 0.05, CADD 10.60
- I45V (p.Ile45Val), gnomAD 10-94938815-A-G, REVEL 0.02, CADD 0.26
- p.Ile45 Gly46insPheProIleSer, gnomAD 10-94938817-A-ATT, CADD 1.92
- I45I (p.Ile45Ile), gnomAD 10-94938817-A-T, CADD 2.12
- G46D (p.Gly46Asp), cosmic curated COSV10729, ExAC rs777883564, TOPMed rs777883564, gnomAD rs777883564, REVEL 0.16, CADD 0.00
- G46V (p.Gly46Val), ExAC rs777883564, TOPMed rs777883564, gnomAD rs777883564, REVEL 0.20, CADD 0.21, Uncertain significance, not specified
- G46S (p.Gly46Ser), gnomAD 10-94938818-G-A, REVEL 0.09, CADD 9.17
- G46R (p.Gly46Arg), gnomAD 10-94938818-G-C, REVEL 0.08, CADD 4.55
- G46A (p.Gly46Ala), gnomAD 10-94938819-G-C, REVEL 0.14, CADD 0.11
- I47T (p.Ile47Thr), Ensembl rs1589403490
- I47V (p.Ile47Val), NCI-TCGA TCGA novel, MetaLR 0.06, MetaSVM -0.99, Variant assessed as somatic; moderate impact.
- I47D (p.Ile47Asp), gnomAD 10-94938820-T-TG, CADD 16.30
- I47M (p.Ile47Met), gnomAD 10-94938822-T-TGA, CADD 17.60
- I47I (p.Ile47Ile), rs749574633, gnomAD 10-94938823-T-C, CADD 0.40
- K48N (p.Lys48Asn), gnomAD 10-94938826-G-T, REVEL 0.09, CADD 14.90
- K48K (p.Lys48Lys), rs755159295, gnomAD 10-94938826-G-A, CADD 2.95
- D49G (p.Asp49Gly), ExAC rs564813580, TOPMed rs564813580, gnomAD rs564813580, REVEL 0.13, CADD 19.50
- D49V (p.Asp49Val), ExAC rs564813580, TOPMed rs564813580, gnomAD rs564813580, REVEL 0.17, CADD 18.80
- D49D (p.Asp49Asp), rs1484571299, gnomAD 10-94938829-C-T, CADD 0.87
- I50V (p.Ile50Val), ExAC rs779187755, gnomAD rs779187755, REVEL 0.01, CADD 0.11
- I50N (p.Ile50Asn), gnomAD 10-94938831-T-A, REVEL 0.05, CADD 22.80
- S51N (p.Ser51Asn), gnomAD rs1267546579, REVEL 0.02, CADD 5.21
- S51R (p.Ser51Arg), gnomAD rs1434716573, REVEL 0.02, CADD 11.80
- S51S (p.Ser51Ser), gnomAD 10-94938835-C-T, CADD 6.85
- K52N (p.Lys52Asn), TOPMed rs2031310014, MetaLR 0.17, MetaSVM -0.88
- K52I (p.Lys52Ile), gnomAD 10-94938837-A-T, REVEL 0.32, CADD 23.30
- S53F (p.Ser53Phe), cosmic curated COSV53248, ExAC rs745738236, gnomAD rs745738236
- S53T (p.Ser53Thr), gnomAD 10-94938839-T-A, REVEL 0.17, CADD 14.50
- S53S (p.Ser53Ser), rs903702017, gnomAD 10-94938841-C-T, CADD 0.12
- L54L (p.Leu54Leu), rs199724614, gnomAD 10-94938842-T-C, CADD 0.44
- T55I (p.Thr55Ile), ExAC rs771905380, TOPMed rs771905380, gnomAD rs771905380, REVEL 0.09, CADD 0.06
- T55A (p.Thr55Ala), gnomAD 10-94938845-A-G, REVEL 0.04, CADD 6.50
- T55T (p.Thr55Thr), rs775312797, gnomAD 10-94938847-C-T, CADD 0.48
- N56S (p.Asn56Ser), ExAC rs746799675, gnomAD rs746799675, REVEL 0.06, CADD 11.50
- N56I (p.Asn56Ile), rs1394457973, gnomAD 10-94938845-AC-A, CADD 0.28
- N56K (p.Asn56Lys), gnomAD 10-94938850-T-A, REVEL 0.09, CADD 0.00
- L57P (p.Leu57Pro), gnomAD rs1458065034, REVEL 0.61, CADD 24.00
- L57S (p.Leu57Ser), gnomAD 10-94938849-AT-A, CADD 19.10
- S58L (p.Ser58Leu), TOPMed rs1045243646, gnomAD rs1045243646, REVEL 0.33, CADD 22.70
- S58S (p.Ser58Ser), gnomAD 10-94941863-A-G, CADD 3.38
- K59* (p.Lys59Ter), gnomAD rs2031390725
- K59E (p.Lys59Glu), gnomAD rs2031390725, REVEL 0.07, CADD 3.41
- K59K (p.Lys59Lys), rs1200269752, gnomAD 10-94941866-G-A, CADD 1.48
- V60A (p.Val60Ala), gnomAD rs1469551263, REVEL 0.15, CADD 0.14
- V60I (p.Val60Ile), ExAC rs747732331, gnomAD rs747732331, REVEL 0.03, CADD 0.24
- V60K (p.Val60Lys), rs767093588, gnomAD 10-94941862-C-CAA, CADD 21.70
- V60V (p.Val60Val), gnomAD 10-94941869-C-T, CADD 2.33
- Y61H (p.Tyr61His), NCI-TCGA Cosmic COSV9958, cosmic curated COSV99583, MetaLR 0.57, MetaSVM 0.37, Variant assessed as somatic; moderate impact.
- Y61Y (p.Tyr61Tyr), gnomAD 10-94941872-T-C, CADD 0.16
- G62D (p.Gly62Asp), rs867193471, NCI-TCGA Cosmic COSV5324, gnomAD rs867193471, REVEL 0.55, CADD 24.90, Variant assessed as somatic; moderate impact.
- G62S (p.Gly62Ser), TOPMed rs1564707283, REVEL 0.47, CADD 25.30
- G62V (p.Gly62Val), gnomAD 10-94941874-G-T, REVEL 0.56, CADD 24.90
- G62G (p.Gly62Gly), gnomAD 10-94941875-C-A, CADD 1.17
- V64M (p.Val64Met), ExAC rs769449338, REVEL 0.55, CADD 23.00
- V64L (p.Val64Leu), gnomAD 10-94941879-G-C, REVEL 0.41, CADD 19.10
- F65L (p.Phe65Leu), gnomAD rs1176755716, REVEL 0.41, CADD 22.90
- T66S (p.Thr66Ser), rs1414631924, gnomAD 10-94941883-TCA-T, CADD 23.60
Public CYP2C9 analysis runs
- CYP2C9 analysis run — CYP2C9 (1,033 variants) — completed 2026-07-21